Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline".

Ann Hepatobiliary Pancreat Surg · 2022 · PMC9721251 · PMID 36372553

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a trend towards significancep = 0.08so close (0.05 < p ≤ 0.1)

16.2 months in the non-NEO group, without observing statistically significant differences between the two but with a trend towards significance in favor of the group treated with neoadjuvant therapy ( p = 0.08) ( Fig. 4 ).

also in 2,760 other papers

a trend toward significancep = 0.08so close (0.05 < p ≤ 0.1)

16.2 months in the non-NEO group, without statistically significant differences between the two but with a trend toward significance (log-rank test p = 0.08).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.